Clinical trialNCT00224393CompletedPhase 2Interventional

Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis

SponsorThe Cleveland ClinicEnrollment60Primary Systemic Amyloidosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the efficacy of Enbrel in patients with primary systemic Amyloidosis.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

John A Lust, MD, PhD
Mayo Clinic
Study Chair
clinicaltrials.gov ↗
Mohamad A Hussein, MD
The Cleveland Clinic
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Etanercept →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Feb 2001
Primary completion: —
Completion: 31 Aug 2005
Last update posted: 30 May 2023
Registered enrollment: 60
Registry id: NCT00224393

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.